Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Shanghai Allist Pharma Completes $174 Million A Round

publication date: May 24, 2019

Shanghai Allist Pharma raised $174 million to expand its drug portfolio in a fundraising led by Shiyu Capital, a China healthcare-focused private equity firm. The round was the first for Allist. Founded in 2005, Allist has a portfolio of drugs for cardiovascular and gastric diseases, many of which include unique delivery technologies. Allist is also developing oncology products including a marketed nanopaclitaxel drug and two pipeline products, a HER-2 targeting agent and an EFGR candidate. The funding will be used for commercialization of new products, new drug research and foreign cooperation. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital